Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Dicerna Pharmaceuticals logo

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

Advanced Chart

Key Stats

Today's Range
$38.22
$38.22
50-Day Range
$37.81
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DRNA Stock News Headlines

Arrowhead Pharmaceuticals (NASDAQ: ARWR)
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
DRNA Jan 2022 22.500 call
DRNA Jul 2022 40.000 call(CONTR
See More Headlines

DRNA Stock Analysis - Frequently Asked Questions

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company earned $62.95 million during the quarter, compared to analysts' expectations of $58.83 million. Dicerna Pharmaceuticals had a negative net margin of 64.53% and a negative trailing twelve-month return on equity of 103.08%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL).

Company Calendar

Last Earnings
11/09/2021
Today
7/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRNA
CIK
1399529
Employees
302
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$112.75 million
Net Margins
-64.53%
Pretax Margin
-63.82%
Return on Equity
-103.08%
Return on Assets
-16.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.46
Quick Ratio
2.46

Sales & Book Value

Annual Sales
$164.31 million
Price / Sales
18.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.84 per share
Price / Book
20.77

Miscellaneous

Outstanding Shares
78,129,000
Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable
Beta
0.80

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:DRNA) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners